BCAL FPO logo

BCAL FPO (BDX)

Market Closed
- Market Cap
- P/E Ratio
3.8% Div Yield
137,348 Volume
- Eps
Earnings results expected in 43 days

Summary

BDX closed today lower, a decrease of 7.69% from yesterday's close, completing a monthly decrease of -23.08%. Over the past 12 months, BDX stock lost -42.86%.
BDX pays dividends to its shareholders, with the most recent payment made on Mar 31, 2025. The next announced payment will be in In 1 weeks on Jun 30, 2025 for a total of A$1.04.
The last earnings report, released on May 01, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.16%, based on the last three reports. The next scheduled earnings report is due on Jul 31, 2025.
The stock of the company had never split.
The company's stock is traded on 14 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Want to track BDX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Becton, Dickinson and Company (BDX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

Becton, Dickinson and Company (BDX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

Becton, Dickinson and Company (NYSE:BDX ) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 2:00 PM ET Company Participants Thomas E. Polen - President, CEO & Chairman Conference Call Participants Robert Justin Marcus - JPMorgan Chase & Co, Research Division Unidentified Analyst Yes.

Seekingalpha | 1 week ago
Becton, Dickinson: A Dividend King Facing Challenges Offers Value

Becton, Dickinson: A Dividend King Facing Challenges Offers Value

Becton, Dickinson is significantly undervalued, trading at 12.3x earnings with a 2.5% dividend yield, the highest in a decade. The company boasts a 53-year streak of dividend growth, excellent dividend safety, and a conservative payout ratio, making it a reliable Dividend King. Despite tariff headwinds, competition, and restructuring risks, BDX's innovation, acquisitions, and organic growth support long-term revenue and EPS expansion.

Seekingalpha | 1 week ago
BD Stock Might See Short-term Decline After Warning on Tamponade Tubes

BD Stock Might See Short-term Decline After Warning on Tamponade Tubes

BDX warns of safety risks tied to its esophagogastric balloon tamponade tubes after one death and two injuries, prompting updated usage instructions for clinicians.

Zacks | 2 weeks ago

BCAL FPO Dividends

Becton, Dickinson and Company logo
BDX 1 weeks ago
Announced
Quarterly
$1.04 Per Share
Becton, Dickinson and Company logo
BDX 3 months ago
Paid
Quarterly
$1.04 Per Share
Becton, Dickinson and Company logo
BDX 6 months ago
Paid
Quarterly
$1.04 Per Share
Becton, Dickinson and Company logo
BDX 9 months ago
Paid
Quarterly
$0.95 Per Share
Becton, Dickinson and Company logo
BDX 10 Jun 2024
Paid
Quarterly
$0.95 Per Share

BCAL FPO Earnings

7 Aug 2025 (50 Days) Date
-
Cons. EPS
-
EPS
31 Jul 2025 (43 Days) Date
-
Cons. EPS
-
EPS
1 May 2025 Date
-
Cons. EPS
-
EPS
30 Jan 2025 Date
2.99
Cons. EPS
3.43
EPS
7 Nov 2024 Date
3.77
Cons. EPS
3.81
EPS
Becton, Dickinson and Company logo
BDX 1 weeks ago
Announced
Quarterly
$1.04 Per Share
Becton, Dickinson and Company logo
BDX 3 months ago
Paid
Quarterly
$1.04 Per Share
Becton, Dickinson and Company logo
BDX 6 months ago
Paid
Quarterly
$1.04 Per Share
Becton, Dickinson and Company logo
BDX 9 months ago
Paid
Quarterly
$0.95 Per Share
Becton, Dickinson and Company logo
BDX 10 Jun 2024
Paid
Quarterly
$0.95 Per Share
7 Aug 2025 (50 Days) Date
-
Cons. EPS
-
EPS
31 Jul 2025 (43 Days) Date
-
Cons. EPS
-
EPS
1 May 2025 Date
-
Cons. EPS
-
EPS
30 Jan 2025 Date
2.99
Cons. EPS
3.43
EPS
7 Nov 2024 Date
3.77
Cons. EPS
3.81
EPS

BCAL FPO (BDX) FAQ

On which exchange is it traded?

BCAL FPO is listed on NYSE.

What is its stock symbol?

The ticker symbol is BDX.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 0.

When is the next earnings date?

The next earnings report will release on Jul 31, 2025.

Has BCAL FPO ever had a stock split?

BCAL FPO had 0 splits and the recent split was on Apr 01, 2022.

BCAL FPO Profile

Medical - Instruments & Supplies Industry
Healthcare Sector
Mr. Thomas E. Polen Jr. CEO
CXA Exchange
US0758871091 ISIN
US Country
70,000 Employees
10 Mar 2025 Last Dividend
1 Apr 2022 Last Split
- IPO Date

Overview

Becton, Dickinson and Company, commonly known as BD, is a global leader in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. Catering to healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public, BD operates worldwide. The company’s extensive product portfolio is strategically segmented into three core areas: BD Medical, BD Life Sciences, and BD Interventional. Founded in 1897, BD has established a robust presence in the healthcare sector, headquartered in Franklin Lakes, New Jersey.

Products and Services

  • BD Medical:

    This segment provides a comprehensive range of products, including peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, and vascular access technology. It also offers vascular care, preparation products, needle-free IV connectors, closed-system drug transfer devices, hazardous drug detections, and a variety of syringes and needles. For drug delivery and safety, it covers IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, as well as automated medication dispensing and supply management systems, enhancing medication inventory optimization and tracking. Additionally, BD Medical produces prefillable drug delivery systems.

  • BD Life Sciences:

    In this area, BD presents an array of solutions for specimen and blood collection and an extensive selection of diagnostic tools, including automated culturing for blood and tuberculosis, molecular testing systems, products for microorganism identification, and drug susceptibility testing. The segment also specializes in liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media products. For cellular analysis, it offers fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, crucial for clinical oncology, immunological research, and transplantation diagnostics or monitoring.

  • BD Interventional:

    BD's interventional segment covers a wide range of surgical and medical products, including those for hernia and soft tissue repair, biosurgery, and surgical infection prevention. It also offers biological and bioresorbable grafts, peripheral intervention products, and equipment for urology and critical care. These products are designed to improve patient outcomes and support the efficiency of medical procedures.

Contact Information

Address: 1 Becton Drive
Phone: 201 847 6800